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In this work, low soluble supramolecular complex between the losartan potassium (Los) and
hydroxypropil--cyclodextrin (HPCD) were characterized throughout phase-solubility, NMR tech-
niques (1H and 2D-ROESY) and isothermal titration calorimetry (ITC) in order to attain physical–chemical
knowledge of the system. In addition, the hypertensive effect of composition Los/HPCD was evaluated
aiming to obtain a more efﬁcient oral pharmaceutical composition. ESI mass spectrometry and ITC blank
experiment demonstrate the presence of Los clusters at 30mM pure solution. Phase-solubility experi-
ments showed a “Bs” type system, due to the formation of a less soluble complex than pure Los. NMRngiotensin II (AT1)
eceptor antagonist
nclusion compounds
yclodextrins
demonstrated the short distance interactions between the Los and the cyclodextrin, where several pos-
sibilities of interactions were observed. ITC data suggest an average 1:1 stoichiometry of Los and the
cyclodextrin. The complex demonstrated efﬁciency in hypertension control, presenting antagonist action
on the pressure effect of angiotensin II within 30h, as compared to Los alone, 6h, indicating that inclu-
sion of Los in HPCD enhanced the extent and duration of its antagonistic action. In this work, a model of
nd H
CD.interaction between Los a
by complexation with HP
. Introduction
Losartan potassium (Los – Fig. 1) is a higher soluble orally active,
on-peptidedrugused in the treatmentofhypertensionandrelated
isorders (Kaplan, 1999; Lambot et al., 2001; Mcintyre et al., 1997;
paril et al., 2001). It has been demonstrated to have a greater
ffect than previous peptide receptor antagonists and angiotensin
onverting enzyme (ACE) inhibitors because of its enhanced speci-
city, selectivity, and tolerability. Los is metabolized in the body,
ormingapharmacologically active carboxylic acidmetabolite EXP-
174 that presents low bio-availability of 33% (19–62%) with an
pproximate one-hour post-administration plasma peak concen-
ration and a mean half-life of 2h (Mcintyre et al., 1997).
∗ Corresponding author at: Departamento de Química, Universidade Federal de
inas Gerais. CEP: 31270-901Avenida Pres.,Antônio Carlos 6627, Belo Horizonte,
inas Gerais, Brazil. Tel.: +55 31 34995778; fax: +55 31 3499 5700.
E-mail address: sinisterra@ufmg.br (R.D. Sinisterra).
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Open access under the Elsevier OA license.PCD was proposed based on dissociation of self-assembled Los followed
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Thus we hypothesized that if sequestering a highly water
soluble drug, such as Los, through supramolecular non-covalent
host–guest complexes formation using modiﬁed cyclodex-
trin, such as hydroxypropil--cyclodextrin (HPCD), we
can obtain lower water Los solubility and a more efﬁcient
angiotensin II AT1 receptor antagonist oral pharmaceutical
composition.
This host–guest strategy is well-established in literature where
cyclodextrins complexes with hydrophobic guests in order to
increase water solubility and bioavailability (De Sousa et al., 2008;
Denadai et al., 2006a, 2007a,b; Irie andUekama, 1997; Loftsson and
Brewster, 1996; Lula et al., 2007; Sousa et al., 2008; Uekama et al.,
1998). However, works using this strategy when water-soluble
molecules as Los are used as guest molecules are scarcely found
in literature.
Open access under the Elsevier OA license.Cyclodextrins are very important for supramolecular chem-
istry, since they form non-covalent complexes with a wide range
of host molecules, which can be used as models for studying
weak interaction. Their cavity offers a suitable hydrophobic envi-
ronment to the guest molecule (Fig. 2), allowing the formation
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f inclusion compounds. Hence cyclodextrins are used for the
olubilization and encapsulation of drugs, perfumes and ﬂavor-
ngs forming supramolecular structures (De Sousa et al., 2008;
enadai et al., 2006a, 2007a,b; Irie and Uekama, 1997; Loftsson
nd Brewster, 1996; Sousa et al., 2008).
In this work, the supramolecular complexes between the Los
nd HPCD were characterized throughout electrospray mass
pectrometry, phase-solubility, NMR techniques (1H and 2D-
OESY) and isothermal titration calorimetry (ITC) in order to look
urther into the physical–chemical characteristics of the system.
urthermore, in vivo anti-hypertensive tests were carried out aim-
ng to assess higher efﬁcient Los oral pharmaceutical composition.
. Materials and methods.1. Reagents
Los was purchased from Galena Química e Farmacêutica Ltda,
razil; and HPCD (substitution degree 5–8 and Mw ≈1400g/mol)
as obtained from Cerestar Company, USA. All the other mate-
Fig. 2. Hydroxipropil--cyFig. 3. Electrospray mass spectroscopy of Losartan potassium 5mM.
rials and solvents were of analytical reagent grade and used as
received.
2.2. Inclusion compound preparation
For NMR and ESI-MS analysis and anti-hypertensive evaluation,
a 1:1 Los/HPCD inclusion compound was prepared by freeze-dry
method. In brieﬂy, the Los salt and HPCD were dissolved in milli-
Q water at 1:1 molar ratio. This mixture was submitted to stirring
during 48h. Next, the solution was freeze-dried by 48h.
2.3. ESI-MS measurements
Mass spectrometry experiments were performed using an ESI
Micromass Q-TOF instrument in order to check the previous aggre-
gation state of the Los and the stoichiometry of the complex in
solution. The data were collected from a 5mM sample of Los and
Los/HPCD 1:1 aqueous solution by using the electrospray ioniza-
tion mode. The standard conditions employed were: vaporization
temperature of 120 ◦C, capillary voltage of 2000V, sample cone
40V, extraction cone 2.0V.
clodextrin structure.
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.4. NMR experiments
1H NMR chemical shifts (ı) and 2D 1H-1H-ROESY experiments
ere obtained using a Brucker DPX-400 Avance (400MHz) spec-
rometer, at 300K.
The solutions used were 2.0mM of Los and 2.0mM (1:1) of
os/HPCD, both dissolved in D2O (Cambridge Isotope Laborato-
ies, Inc – 99.9% of isotopic purity). The HOD signal at ı=4.80 was
sed as reference. No solid formation was observed in the solution
uring analysis. The 2D-ROESY experiments were recorded at spin
ock of 600ms, which was previously calculated throughout the
nversion-recovery sequence (Rahman, 1989; Werner, 1994).
The sample for this experiment was prepared by utilizing the
reezing-drying method in the molar ratio of 1:1 Los/HPCD. In
his method, the aqueous solution, which contains the dissolved
aterials (Los and HPCD), was stirred for 2h. After, the solu-
ion was frozen in liquid nitrogen and freeze-dried for 24h before
issolution in D2O.
.5. Solubility studies
The phase-solubility diagrams were made according to the
iguchi and Connors method (Higuchi and Connors, 1969). For
his purpose, aqueous solutions of HPCD with concentrations of
–2.6mM with a known concentration of Los at 30mM were pre-
ared. These were placed in a thermostatic bath at 298K by 48h.
he sampleswerecentrifugedat15 rpmfor10minandﬁlteredwith
n ultra-ﬁltrationmembrane of 0.22mfromMillipore®. Quantiﬁ-
ationwas performed in triplicate on aUV–vis equipment HP-8453
t 248nm and a one-centimeter cell.ansion of the region between 1800 and 2000, referent to inclusion compounds.
2.6. Microcalorimetric measurements
Calorimetric titrations were carried out in duplicate with a VP-
ITC Microcalorimeter (Microcal Company, Northampton, MA, USA)
at 298.15; 303.15 and 308.15K next the electrical and chemical
calibration.
Each titration experiment consisted of 41 successive injections
of Los aqueous solution (100mM) into the reaction cell charged
with 1.6mL of HPCD aqueous solution (4.0mM), with time inter-
vals of 540 s. The ﬁrst injection of 1.0L was discarded to eliminate
diffusion effects of material from syringe to cell calorimetric. The
subsequent injections were used at constant volume of 5.0L of
Los. The time of injection was 2.0 s.
TheHPCD concentration in the calorimeter cell varied from4.0
to 3.6mM and the concentration of the Los from 0.0 to 11.1mM.
The raw data were analyzed using the “one site model” set forth
by Microcal Origin 5.0 for ITC after the subtraction of the blank
experiment (dilution of Los in water).
The enthalpy values obtained at each temperature were plot-
ted against temperature values in order to determinate the heat
capacity at pressure constant C ◦ p, according to Eq. (1), where the
angular coefﬁcient of the curve ∂H◦/∂T, was obtained by linear
regression by using of Microcal Origin 5.0.
C◦p =
(
∂H◦
∂T
)
p
(1)2.7. Dissolution tests
The dissolution tests were performed in an incubator model
Q120A3 Qualitas according to the method described by Oskan
et al. (2000). Initially were weighed in triplicate 100mg of Los
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nd 300mg of the freeze dried Los/HPCD, after being passed by a
eparation particle size of 50, 100 and 200mesh. They were then
ransferred to tubes eppendorfs and added 2.0mL of phosphate
uffer pH 7.4 and undergoing agitation 110 rpm at 37 ◦C for 5min.
hen 1.0mL was collected from each tube and added more 1.0mL
f buffer. This procedure was performed at various time intervals
0.25–24h) after the beginning of the experiment, reaching 48h.
he solutions collected from each tube at different time intervals
ere stored for quantiﬁcation on a UV–vis equipment HP-8453 at
48nm and a one-centimeter cell.
.8. Antagonist action of Los and Los/HPˇCD complex on the
ressor effect of angiotensin II in Wistar rats
The antagonist action of Los and Los/HPCD complex on
ngiotensin pressor effect was evaluated in Wistar rats (male,
eighting300–350g) obtained from“CEBIO–CentrodeBioterismo
e Ciências Biológicas–UFMG”.Before and after surgery, the animals were kept in a
emperature-controlled room using a 14/10-light/dark cycle. One
ay before the experiment, a polyethylene catheter (PE-10 con-
ected to PE-50)was inserted into the abdominal aorta through the
emoral artery for blood pressure measurements. For intravenous
Fig. 6. 2D-ROESY spectrum of the inclusion cof Pharmaceutics 404 (2011) 116–123 119
injections and infusions, polyethylene cannulas were implanted
into the veins. The cannulas, closed by a metallic pin and ﬁlled with
isotonic saline, were driven subcutaneously to the interdescapular
region of the back of the animals. After recovery from anesthesia,
the rats were kept in individual cages with free access to water and
chow until the end of the experiment. A data acquisition system
(Biopac, USA) was used to measure systolic, diastolic and mean
pressure. In experiments, Los/HPCD solution was prepared by
directly dissolution of complex in mili-Q water, which was fol-
lowed by further dilutions. Los and Los/HPCD were administered
by oral route, and the hypertensive effect produced by i.v. infusion
of angiotensin II (Ang II) (0.10mL 20ng in bolus). The pressure data
were collected 2, 6, 12, 24, 48 and 72h after Los or Los/HPCD com-
plex administration. All experimental protocols were performed
in compliance with the guidelines on laboratory animals from our
institute and approved by local authorities.
The basal values mean arterial pressure were (98±0.5) mmHg.
Comparisons between the control period and the experimental and
recovery periods were made by one-way ANOVA, followed by the
Dunnet’s test. For this, the control values were obtained by averag-
ing all values obtained in the last 3 days of the pre-infusion period.
Comparison between changes in mean arterial pressure produced
by Ang II infusion was made using t-test. A value of P<0.05 was
considered statistically signiﬁcant.
3. Results and discussion
3.1. ESI-MS measurements
Los is an amphiphilic substance and shows an intense and
endothermic heat of dilution (see below ITC data) suggesting dis-
aggregating phenomenon upon dilution. Hence, in order to check
the possibility of self-assembly of the Los under the experimen-
tal conditions, ESI mass-spectrometry measurements were used
once the ESI experiments were able to evaluate weak non-covalent
complexes (Fig. 3) (Rekharsky et al., 2002; Toma et al., 2004).The data presented in Fig. 3 show the presence of homologue
series of small Kn−1Losn clusters, not excluding necessarily the
presence of high order self-assembly complexes in water solu-
tions, as described in the literature for other amphiphilic systems
(Rekharsky et al., 2002; Toma et al., 2004).
mpound between Losartan and HPCD.
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Table 1
1H NMR (at 400MHz) chemical shifts of Los and Los/HPCD in D2O at 27 ◦C.
Hydrogen ıLos ıLos/HPCD ıa
H6 2.49 2.51 +0.02
H7 1.48 1.40 −0.08
H8 1.25 1.20 −0.05
H9 0.81 0.79 −0.02
H10 5.21 5.24 +0.03
H12 6.90 6.97 +0.05
H13 7.10 7.16 +0.04
H16 7.29 7.28 −0.01
H17 7.34 7.36 +0.02
H18 7.36 7.37 +0.01
H19 7.52 7.54 +0.02
scale of NMR detection,
(3) self-assembly of inclusion compounds, where the complex will
be packaged in different way, stabilized by hydrogen bonds.20 W.X. de Paula et al. / International Jou
ESI mass-spectroscopy was also used to assess qualitatively the
pecies present in the Los/HPCD solution at a 1:1 molar ratio
Fig. 4). The ESI technique is not precise enough to monitor weak
on-covalent interactions because this type of experiment may
isturb the chemical equilibrium of the system due to the drastic
onditions (high electrical ﬁeld and high temperature).
Fig. 4 shows parts of the ESI experiment where the m/z distri-
ution of peaks between 1285.45 and 1713.90, with maximum at
537.64, is observed. Such distribution is due the fact that HPCD
ample is a mixture of several cyclodextrins with different substi-
ution degree. At m/z values localized between 1800 and 2000 is
bserved three peaks, 1846.13, 1905.28 and 1963.45, relating to
hree types of inclusion compounds with stoichiometry 1:1. The
orrespondent peaks of free cyclodextrins are those localized atm/z
423.54, 1479.58 and 1537.64 (considering the m/z of Los− anion
f 423.32).
.2. Phase solubility studies
Thermodynamic solubility experiments allow to demonstrate
he hydrotrope effect on the solubility of a substance and evaluates
he interactions between the species (Higuchi and Connors, 1969).
Fig. 5 shows the solubility of Los against HPCD concentra-
ion where an initial Los constant concentration of up to 0.25mM
f cyclodextrin is observed. After achieving this value, a strong
eduction of Los solubility upon increase of HPCD concentration
s observed. This diagram corresponds to the formation of a com-
lex less soluble than the pure substrate, named Higuchi’s Bs type
Higuchi and Connors, 1969).
Los and HPCD are very soluble molecules presenting high
queous solubility at 298K (both species have solubility greater
han 300mM). However, as demonstrated in Fig. 5, a lower
oluble than pure Los species is formed upon complexation,
howing stronger host–guest interaction than host–solvent and
uest–solvent.
The Los/HPCD complex is a very small and quasi invisible pre-
ipitate which was separated from solution only by centrifugation
nd ultra-ﬁltration. According to the solubility data, the precipi-
ate formation is dependent on the molar ratio and it starts to form
bove 0.25mM of HPCD.
The Los solubility reduction after the HPCD interaction could
e explained by the ESI results for pure Los. The ESI results showed
he presence of Los self-assemblies, which could be an intrinsic sol-
bilization mechanism of the drug. Thus, complexation of Los with
PCD could break down the self-assemblies, leading to reduction
f Los solubility.
.3. NMR experiments
NMR experiments allowed an investigation of the short dis-
ance interaction of supramolecular complexes between Los and
PCD. 1H NMR chemical shift changes are related to the distur-
ance caused by unpaired C1-O-C4 electrons of the HPCD cavity
n electronic density of the Los hydrogen’s (De Sousa et al., 2008;
enadai et al., 2007b; Loftsson et al., 1993; Schneider et al., 1998;
ousa et al., 2008). Changes in chemical environment and confor-
ation upon break down of self-assembly also contribute to the
hanges in chemical shift. The Table 1 shows the chemical shift of
H NMR values for free and complexated Los.
Possible architectures of the Los complexes with cyclodextrins
ere evaluated by the 2D-ROESY experiments, which are able to
etect dipolar coupling in solution through space upon 5 A˚ distance
Denadai et al., 2007a,b; Lula et al., 2007; Rahman, 1989; Schneider
t al., 1998; Werner, 1994).
Cross peaks correlations were found between aromatic Los
ydrogens (region at ı ≈6.5–7.6) with H2, H3, H4, H5 and H6H22 4.31 4.30 −0.01
a ı= ıLos − ıLos/HPCD.
HPCD hydrogens. There were also cross peaks found between
H12, H13 and H16 of the Los with H9 hydrogens of HPCD hydrox-
ypropyl group. These data are indicating correlations of aromatic
and aliphaticmoieties of Loswith external hydrogens H9 of HPCD
(Fig. 6).
These results suggest very complex supramolecular architecture
between Los andHPCDwhich could be explained in termsof three
plausible hypotheses:
(1) dynamic equilibrium between the species, where several com-
plexes stabilized by different non-covalent interactions can
exist within the time scale of NMR detection,
(2) conformational equilibrium of Los molecule, which could let
several kinds of interactionswith cyclodextrinswithin the timeFig. 7. Dilution curves obtained from 41 successive 5L injections of an aqueous
solution of 100mM Losartan potassium into a 1.4mL cell containing water at 298,
308 and 318K.
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.4. Microcalorimetric measurements
In order to know the average stoichiometry of the complex
n solution as well as its thermodynamic parameters, isothermal
itrations calorimetry (ITC) of Los 100mM into the 4mM HPCD
olution, at 298, 308 and 318K were performed (Figs. 7 and 8).
TC experiment allows for the simultaneous determination of the
nthalpyH◦, equilibriumconstantKeq and stoichiometryN froma
ingle titration curve, using the least square non-linear adjustment
MicroCal, 1998a,b; Turnbull and Daranas, 2003). Through the use
f classical thermodynamic equations (Levine, 1995), is possible
alculate the changes on free energy G◦, entropy energy TS◦
nd heat capacity at pressure constant C ◦ p.
For all temperatures, the sigmoid adjust showed an equivalence
oint at molar ratio of approximately 0.8 (Table 2). These data and
he relative size between the molecules suggested a 1:1 minimal
toichiometry not necessarily excluding the existence of higher
rder complex.
It is well accepted in the literature that the cyclodextrin system
here is a distribution of equilibrium species, named Losn/HPCDm,
ich has an average stoichiometry (Denadai et al., 2007b; Loftsson
nd Brewster, 1996; Sousa et al., 2008). Thus, the equilibrium
onstant calculated on the basis of ITC experiment is a global equi-
ibrium constant Keq,g, referring to some process which leads to the
ormation of a Losn/HPCDm (Eqs. (2) and (3)).
S + mCDKeq,g SmCDn (2)
able 2
hermodynamic parameters obtained by ITC experiments.
T/K N K H◦/kJmol−1
298.15 0.74 1147.0 −11.8
308.15 0.79 739.2 −13.4
318.15 0.83 496.8 −14.7Fig. 9. C ◦ p calculus from Eq. (1).
Keq,g = [SmCDn]
[S]n[CD]m
(3)
As depicted in Fig. 7, the Los dilution experiment showed
endothermic signals in an overall range of analyzed concentration,
indicating that dilution is entropy-driven.
Considering that ESI mass spectroscopy experiments showed
the presence of clusters at 30mM solutions, the endothermic dilu-
tion of Los could be understood in terms of disaggregation of
self-assemblies,which requires energy to separatemonomers from
the clusters.
Analyzing the data fromTable 2, one canobserve that the overall
interaction between Los and HPCD is exothermic and accompa-
nied by entropy increase. However, the global equilibriumconstant
is relatively low and similar to other cyclodextrins/guest systems
(Rekharsky and Inoue, 1998).
Enthalpy changes may well be attributed to the binding of
enthalpy-rich water molecules released from the cyclodextrin cav-
ity together with bulk water molecules (De Sousa et al., 2008;
Denadai et al., 2006b, 2007a,b; Loftsson and Brewster, 1996;
Rekharsky and Inoue, 1998; Sousa et al., 2008), by the formation
of cooperative Van der Waals interactions between guest and the
cyclodextrin cavity through the hydrophobic Los moiety and by
the formation of ion-dipole interaction between tetrazolic ring and
cyclodextrin OH groups.
By performing ITC experiments, positive entropy changes were
found, although the Los/HPCD complex had been precipitated.
For an increase of entropy in the precipitation process, high des-
solvation of molecules is needed to compensate the formation of
solid-state phase, and the water molecules must gain translational
and rotational freedom degree (Rekharsky et al., 2002).
The deepest understanding of the host–guest interactions was
achieved by considering the Cp changes during the process, cal-
culated by Eq. (1) through linear regression in a “H◦ versus T”
graphic (Fig. 9).It iswell known thatCp data is related to changes inhydropho-
bic interactions during binding process. According to the literature
(Rekharsky and Inoue, 1998), if Cp is negative (−0.15kJ/molK for
the Los/HPCD system), hydrophobic bonds are formed as con-
G◦/kJmol−1 TS◦/kJmol−1 Cp/kJmol−1K−1
−17.5 5.8
−16.9 3.5 −0.15
−16.4 1.7
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Fig. 11. Effect of Losartan and Los/HPCD complex administered by oral route at
ig. 10. Dissolution proﬁle of Losartan and Los/HPCD complex.Mean± SE (vertical
ar), n=3.
equence of breakdown water clatrates around apolar molecules,
orroborating the dessolvation hypothesis mentioned above.
Thus, in thiswork it was suggested that the interaction between
os and HPCD involves an initial disaggregation of Los self-
ssemblies, followed by complexation with cyclodextrins. The
ormedcomplexpresents lowsolubility and it is stabilizedby favor-
ble interactions such as Van der Waals, hydrogen bonding and
on-dipole interactions. The interaction is increased by the release
f the enthalpy-richwatermolecules fromcyclodextrins cavity and
ydration shells of cyclodextrins and Los, which gain rotational
nd translational freedom degree in order to overcome the entropy
eduction due to precipitation.
.5. Dissolution tests
Fig. 10 shows the in vitro dissolution proﬁles for Losartan and
os/HPCD. The curve of Losartan showed a rapid dissolution, with
pproximately 100% dissolved in the ﬁrst minutes, as compared to
5% dissolution of Los/HPCD at the same time interval. Moreover,
he dissolution of the complex was observed until 20h after the
tart of testing, conﬁrming that inclusion leads to a decrease in
olubility of Losartan.
.6. Antagonist action of Los and Los/HPˇCD complex on the
ressor effect of angiotensin II in Wistar rats
Fig. 11 shows the antihypertensive effect of Los and Los/HPCD
n Wistar rats. The Los/HPCD complex, when administered orally
s a single dose of 0.7mg/kg, blocked in approximately 75%
p<0.01, n=4) the pressor effect of Ang-II for approximately 30h.
n contrast, the free Los given at the same dose blocked the effect of
ng II for a period of only 6h (p<0.01, n=4). The increase in pres-
ure due to angiotensin II administration in the control period was
0.2mmHg and 22.3mmHg for Los and Los/HPCD, respectively.
fter 3h, 13mmHg and 9mmHg, reaching around a variation of
0.5mmHg and 17.1mmHg after 30h.
These data indicate that inclusion compound Los/HPCD
nhanced the extent and duration of its Los antagonist action. The
igher Los bioavailability upon inclusion could be due to the lower
os solubility and solubilization rate as veriﬁed by phase solubility
tudies and dissolution tests.
To the extent of our knowledge, such an approach to alter the
harmacological proﬁle of highly water-soluble drug when admin-
stered orally has not yet been explored. Thus, the formulation
sing the host–guest strategy could be improved by increasing the
fﬁcacy and reducing the dose or spacing with each dose intake.0.7mg/kg to Wistar rats, on the mean arterial pressure changes induced by Ang II
(20ng i.v.). *p<0.05 compared with the average of the 3 last day of the period before
infusion (98±0.5mmHg) (ANOVA followed by Dunnett’s test). Mean± SE (vertical
bar), n=4.
4. Conclusion
A model based on dissociation of the Losartan potassium clus-
ters, followed by complexation with HPCD forming a lower
soluble 1:1 complex than their precursor has been proposed.
This approach offers an alternative means of improving the bio-
availability ofwater-soluble drugs and represents a signiﬁcant step
towards the development of sustained release of oral dosage forms.
The Los formulation accompaniedwith this strategy could beuseful
in reducing costs and increasing compliancewith the antihyperten-
sive treatment.
Acknowledgments
The authors acknowledge ﬁnancial support by Brazilian agen-
cies FAPEMIG, CAPES and CNPq and Biolab-Sanus pharmaceutical
company for the technology transfer contract assigned with the
UFMG to scale up this technology.
References
De Sousa, F.B., Denadai, A.M., Lula, I.S., Lopes, J.F., Dos Santos, H.F., De Almeida,
W.B., Sinisterra, R.D., 2008. Supramolecular complex of ﬂuoxetine with beta-
cyclodextrin: an experimental theoretical study. Int. J. Pharm. 353, 160–169.
Denadai, A.M., Ianzer, D., Alcantara, A.F., Santoro, M.M., Santos, C.F., Lula, I.S., de
Camargo, A.C., Faljoni-Alario, A., dos Santos, R.A., Sinisterra, R.D., 2007a. Novel
pharmaceutical composition of bradykinin potentiating penta peptide with
beta-cyclodextrin: physical–chemical characterization and anti-hypertensive
evaluation. Int. J. Pharm. 336, 90–98.
Denadai, A.M., Teixeira, K.I., Santoro, M.M., Pimenta, A.M., Cortes, M.E., Sinisterra,
R.D., 2007b. Supramolecular self-assembly of beta-cyclodextrin: an effec-
tive carrier of the antimicrobial agent chlorhexidine. Carbohydr. Res. 342,
2286–2296.
Denadai, A.M.L., Santoro, M.M., Da Silva, L.H., Viana, A.T., Santos, R.A.S., Sinis-
terra, R.D., 2006a. Self-assembly characterization of the beta-cyclodextrin and
hydrochlorothiazide system: NMR, phase solubility, ITC and QELS. J. Incl. Phe-
nom. Macro. 55, 41–49.
Denadai, A.M.L., Santoro, M.M., Lopes, M.T.P., Chenna, A., de Sousa, F.B., Avelar, G.M.,
Gomes, M.R.T., Guzman, F., Salas, C.E., Sinisterra, R.D., 2006b. A supramolecular
complex between proteinases and beta-cyclodextrin that preserves enzymatic
activity – physicochemical characterization. Biodrugs 20, 283–291.
Higuchi, T., Connors, K., 1969. Phase-Solubility Techniques. Advances in Analytical
Chemistry and Instrumentation, 4, pp. 117–212.
Irie, T., Uekama, K., 1997. Pharmaceutical applications of cyclodextrins 3. Toxicolog-
ical issues and safety evaluation. J. Pharm. Sci. 86, 147–162.
Kaplan, N.M., 1999. Angiotensin II receptor antagonists in the treatment of hyper-
tension. Am. Fam. Physician 60, 1185–1190.
Lambot, M.A., Vermeylen, D., Noel, J.C., 2001. Angiotensin-II-receptor inhibitors in
pregnancy. Lancet 357, 1619–1620.
Levine, I.N., 1995. Physical Chemistry, fourth edition.McGRAW-HILL INC., NewYork.
Loftsson, T., Brewster, M.E., 1996. Pharmaceutical applications of cyclodextrins 1.
Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017–1025.
rnal o
L
L
M
M
M
O
O
RW.X. de Paula et al. / International Jou
oftsson, T., Olafsdottir, B.J., Frioriksdottir, H., Jonsdottir, S., 1993. Cyclodextrin com-
plexation of Nsaids – physicochemical characteristics. Eur. J. Pharm. Sci. 1,
95–101.
ula, I., Denadai, A.L., Resende, J.M., de Sousa, F.B., de Lima, G.F., Pilo-Veloso,
D., Heine, T., Duarte, H.A., Santos, R.A., Sinisterra, R.D., 2007. Study of
angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion com-
plexes: complete sequence-speciﬁc NMR assignments and structural studies.
Peptides 28, 2199–2210.
cintyre, M., Caffe, S.E., Michalak, R.A., Ried, J.L., 1997. Losartan, an orally active
angiotensin (AT1) receptor antagonist: a review of its efﬁcacy and safety in
essential hypertension. Pharmacol. Ther. 74, 181–194.
icroCal, 1998a. ITC data analysis in originr tutorial guide. In: MicroCal (Ed.), The
Calorimetry Experts, 5.0 ed. MicroCal, www. microcalorimetry. com.
icroCal, 1998b. VP-ITC microcalorimeter. User’s manual. In: The Calorimetry
Experts. MicroCal, www. microcalorimetry. com.
paril, S., Aurup, P., Snavely, D., Goldberg, A., 2001. Efﬁcacy and safety of losar-
tan/hydrochlorothiazide in patients with severe hypertension. Am. J. Cardiol.
87, 721–726.
skan, Y., Atay, T., Dikmen, N., Isimer, A., 2000. Improvement of water solubility
and in vitro dissolution rate of glicazide by complexation with -cyclodextrin.
Pharm. Acta Helv. 74, 365–370.
ahman, A., 1989. One andTwoDimensionalNMRSpectroscopy. Elsevier, NewYork.f Pharmaceutics 404 (2011) 116–123 123
Rekharsky, M., Inoue, Y., Tobey, S., Metzger, A., Anslyn, E., 2002. Ion-pairing
molecular recognition in water: aggregation at low concentrations that is
entropy-driven. J. Am. Chem. Soc. 124, 14959–14967.
Rekharsky, M.V., Inoue, Y., 1998. Complexation thermodynamics of cyclodextrins.
Chem. Rev. 98, 1875–1917.
Schneider, H.J., Hacket, F., Rudiger, V., Ikeda, H., 1998. NMR studies of cyclodextrins
and cyclodextrin complexes. Chem. Rev. 98, 1755–1785.
Sousa, F.B.d., Denadai, Â.M.L., Lula, I.S.e., Nascimento, C.S., Neto, N.S.G.F., Lima,
A.C., Almeida, W.B.d., Sinisterra, R.D., 2008. Supramolecular self-assembly of
cyclodextrin and higher water soluble guest: thermodynamics and topological
studies. J. Am. Chem. Soc. 130, 8426–8436.
Toma, S.H., Uemi, M., Nikolaou, S., Tomazela, D.M., Eberlin, M.N., Toma, H.E., 2004.
{trans -1,4-bis[(4-pyridyl)ethenyl]benzene}(2,2′-bipyridine)ruthenium(II)
complexes and their supramolecular assemblies with beta-cyclodextrin. Inorg.
Chem. 43, 3521–3527.
Turnbull, W.B., Daranas, A.H., 2003. On the value of c: can low afﬁnity sys-
tems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 125,
14859–14866.
Uekama, K., Hirayama, F., Irie, T., 1998. Cyclodextrin drug carrier systems. Chem.
Rev. 98, 2045–2076.
Werner, M.H., 1994. Advance User’s Guide, Brucker. Spectrospin AG, Fallanden,
940712.
